摘要
运用网状Meta分析评价8种口服中成药治疗慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease, AECOPD)的疗效与安全性。计算机检索中国知网(CNKI)、万方(Wanfang)、维普(VIP)、中国生物医学文献服务系统(SinoMed)、PubMed、Web of Science、EMbase、Cochrane Library数据库中8种口服中成药治疗AECOPD的随机对照试验(RCT),检索时间为建库至2022年8月6日。提取纳入文献信息,通过Cochrane风险偏倚评估工具对纳入研究进行质量评价,采用Stata SE 15.1、ADDIS 1.16.8软件进行数据分析。最终纳入53篇RCTs,样本量5 289例,试验组2 652例,对照组2 637例。网状Meta分析显示,在提高临床有效率方面,连花清瘟胶囊+常规西医效果最好;在提高第1秒用力呼气量占用力肺活量百分比(FEV1/FVC)方面,疏风解毒胶囊+常规西医效果最好;在提高第1秒用力呼气量占预计值百分比(FEV1%pred)方面,清气化痰丸+常规西医效果最好;在提高动脉氧分压(PaO_(2))方面,肺力咳合剂(胶囊)+常规西医效果最好;在降低动脉二氧化碳分压(PaCO_(2))方面,连花清瘟胶囊+常规西医效果最好;在降低C反应蛋白(CRP)方面,清气化痰丸+常规西医效果最好。安全性方面,大多以消化道症状为主,且均未报道严重不良反应。将临床有效率作为疗效评价的综合指标,连花清瘟胶囊+常规西医成为AECOPD最佳治疗措施的可能性最大。该研究结论存在一定局限性,对临床用药仅提供参考。
This study aimed to evaluate the effectiveness and safety of eight oral Chinese patent medicines in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD)by network Meta-analysis.Randomized controlled trial(RCT)on the treatment of AECOPD with eight oral Chinese patent medicines was retrieved from databases including CNKI,Wanfang,VIP,SinoMed,PubMed,Web of Science,EMbase,and Cochrane Library from database inception to August 6,2022.The information was extracted from the included literature and the quality of the included studies was evaluated using the Cochrane risk of bias assessment tool.The data were analyzed using Stata SE 15.1 and ADDIS 1.16.8 software.Finally,53 RCTs were included,with 5289 patients involved,including 2652 patients in the experimental group and 2637 patients in the control group.Network Meta-analysis showed that Lianhua Qingwen Capsules+conventional western medicine were optimal in improving clinical effective rate,Shufeng Jiedu Capsules+conventional western medicine in improving FEV1/FVC,Qingqi Huatan Pills+conventional western medicine in improving FEV1%pred,Feilike Mixture(Capsules)+conventional western medicine in improving PaO_(2),Lianhua Qingwen Capsules+conventional western medicine in reducing PaCO_(2),and Qingqi Huatan Pills+conventional western medicine in reducing C-reactive protein(CRP).In terms of safety,most of them were gastrointestinal symptoms,and no serious adverse reactions were reported.When the clinical effective rate was taken as the comprehensive index of efficacy evaluation,Lianhua Qingwen Capsules+conventional western medicine were the most likely to be the best treatment for AECOPD.There are some limitations in the conclusion of this study.It only provides references for clinical medication.
作者
丁梦瑶
杨曙光
于宁霞
洪赟晢
叶子春
余学庆
DING Meng-yao;YANG Shu-guang;YU Ning-xia;HONG Yun-zhe;YE Zi-chun;YU Xue-qing(Henan University of Chinese Medicine,Zhengzhou 450046,China;the First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou 450000,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2023年第12期3373-3385,共13页
China Journal of Chinese Materia Medica
基金
国家自然科学基金重点项目(81973779,82174307)
河南省首批中医药拔尖人才培养项目(2019ZYBJ02)
河南省自然科学基金青年项目(222300420223)。
关键词
口服中成药
慢性阻塞性肺疾病急性加重期
网状Meta分析
oral Chinese patent medicine
acute exacerbation of chronic obstructive pulmonary disease
network Meta-analysis
